BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36193597)

  • 1. CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer.
    Khan A; Sarkar E
    Cancer Treat Res Commun; 2022; 33():100641. PubMed ID: 36193597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erratic journey of CRISPR/Cas9 in oncology from bench-work to successful-clinical therapy.
    Sarkar E; Khan A
    Cancer Treat Res Commun; 2021; 27():100289. PubMed ID: 33667951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy.
    Naeem M; Hazafa A; Bano N; Ali R; Farooq M; Razak SIA; Lee TY; Devaraj S
    Life Sci; 2023 Mar; 316():121409. PubMed ID: 36681183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
    Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
    Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management.
    Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Al Abdulmonem W; Moawad AA; Alwanian WM; Almansour NM; Rahmani AH; Khan AA
    Int J Nanomedicine; 2023; 18():5531-5559. PubMed ID: 37795042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
    Dimitri A; Herbst F; Fraietta JA
    Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9 technology: towards a new generation of improved CAR-T cells for anticancer therapies.
    Ureña-Bailén G; Lamsfus-Calle A; Daniel-Moreno A; Raju J; Schlegel P; Seitz C; Atar D; Antony JS; Handgretinger R; Mezger M
    Brief Funct Genomics; 2020 May; 19(3):191-200. PubMed ID: 31844895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology.
    Andreu-Saumell I; Rodriguez-Garcia A; Guedan S
    Methods Mol Biol; 2024; 2748():151-165. PubMed ID: 38070114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.
    Chen M; Xu J; Zhou Y; Zhang S; Zhu D
    Brief Funct Genomics; 2020 May; 19(3):183-190. PubMed ID: 31788683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy.
    Quazi S
    Mol Biol Rep; 2022 Jul; 49(7):7069-7077. PubMed ID: 35122203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
    Li C; Mei H; Hu Y
    Brief Funct Genomics; 2020 May; 19(3):175-182. PubMed ID: 31950135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer.
    Kavousinia P; Ahmadi MH; Sadeghian H; Hosseini Bafghi M
    Cytotherapy; 2024 May; 26(5):436-443. PubMed ID: 38466263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better living through chemistry: CRISPR/Cas engineered T cells for cancer immunotherapy.
    Wellhausen N; Agarwal S; Rommel PC; Gill SI; June CH
    Curr Opin Immunol; 2022 Feb; 74():76-84. PubMed ID: 34798542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy.
    Ghaffari S; Khalili N; Rezaei N
    J Exp Clin Cancer Res; 2021 Aug; 40(1):269. PubMed ID: 34446084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
    Wu HY; Cao CY
    Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies.
    Maganti HB; Kirkham AM; Bailey AJM; Shorr R; Kekre N; Pineault N; Allan DS
    Cytotherapy; 2022 Apr; 24(4):405-412. PubMed ID: 35039239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
    Liu X; Zhao Y
    Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy.
    Gao Q; Dong X; Xu Q; Zhu L; Wang F; Hou Y; Chao CC
    Cancer Med; 2019 Aug; 8(9):4254-4264. PubMed ID: 31199589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR/Cas9-based genome editing in the era of CAR T cell immunotherapy.
    Salas-Mckee J; Kong W; Gladney WL; Jadlowsky JK; Plesa G; Davis MM; Fraietta JA
    Hum Vaccin Immunother; 2019; 15(5):1126-1132. PubMed ID: 30735463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
    Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
    J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.